Exhibit 99.2

Kazia Therapeutics Limited ("Kazia") is a Sydney-based clinical-stage oncology company focused on high- need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need. Financial Insights Cash & Cash Equivalents: ~ US$46 million (Runway expected to fund planned operations into 2029, excluding additional or expanded trials) Debt: No outstanding debt Ticker: KZIA (NASDAQ) American Depository Shares Outstanding: ~ 11.4 million Key Investment Highlights • Portfolio/Pipeline: The portfolio includes two clinical-stage small- molecule programs: (1) paxalisib, a brain-penetrant dual inhibitor of the PI3K/AKT/mTOR pathway, a critical signaling route that helps cancer cells grow and multiply, licensed from Genentech, and (2) EVT801, a selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor discovered by Sanofi and licensed from Evotec SE. Additionally, Kazia has an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader platform (lead compound NDL2), alongside worldwide rights to combination IP that covers pairing PI3K inhibitors with other cancer therapies including immunotherapies and PARP inhibitors. • Partnerships and Collaborations: Simcere (Greater China), Sovargen (select neurology), QIMR Berghofer (first-in-class PD- L1 degrader platform, research collaborations), Pacific Pediatric Neuro-Oncology Consortium, Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, and Dana-Farber Cancer Institute. • Proven Leadership: Dr. John Friend, CEO, and Jeffrey Kraws, Head of Corporate Strategy & Development, bring clinical, operational, and market expertise to support current and future phases of development. • Intellectual Property: Kazia and its partners maintain a global intellectual property portfolio supporting development and durable competitive positioning. Beyond Inhibition. Reprogramming Cancer Control. Disclaimer: This Fact Sheet may contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this Fact Sheet, including statements regarding our expectations of our financial results for the six months ended December 31, 2025, clinical trial results, strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Kazia's control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including risks related to clinical trial delays, failure to achieve desired endpoints, regulatory setbacks or delays, financing risks, our dependence on certain partners and collaborators and clinical data variability, and other risks including the risks detailed in the filings we make with the Securities and Exchange Commission from time to time, including under the heading "Risk Factors" in our most recent Annual Report of Form 20-F. There can be no assurance that the future developments affecting Kazia Therapeutics will be those that we have anticipated. Except as required by law, Kazia Therapeutics does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Furthermore, this Fact Sheet is intended to be used solely for informational purposes and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. Some of the information contained in this Fact Sheet may be derived from industry sources. While we believe that such information is accurate and that the sources from which it has been obtained are reliable, we cannot guarantee the accuracy of such information, as we have not independently verified such information.

Q4 2025 Pricing of $50 million private placement of equity securities Q1 2026 Clinical trial update; Complete metabolic response in stage IV TNBC expanded access patient and 2 partial responses in metastatic TNBC Phase 1b study Q1 2026 PD-L1 protein degrader platform update Q2 2026 Update from FDA discussion regarding paxalisib commercial and development path forward in GBM Q2 2026 Advancement of NDL2 PD-L1 degrader program toward IND-enabling studies 2H 2026 Readouts from neuro-oncology focused clinical trials in patients with GBM and brain metastases 2H 2026 Clinical efficacy and biomarker data from ongoing Phase 1b breast cancer study 2H 2026 Provide update of paxalisib pre-clinical development into additional breast cancer subtypes 2H 2026 Publication/Presentation of translational data supporting therapeutic reprogramming strategy for paxalisib Pipeline Snapshot ir@kaziatherapeutics.com Milestones & Anticipated Catalysts MARCH 2026 | Rev 02 www.kaziatherapeutics.com